natgillin/translations-raw huggingface dataset:
Personal history of myopathy and/or rhabdomyolysis with statins and/or fibrates or confirmed creatine phosphokinase (CK) elevation above 5 times the ULN under previous statin treatment (see section 4.4).
Miopatija in/ali rabdomioliza ob jemanju statinov in/ali fibratov v osebni anamnezi ali potrjeno zvišanje kreatin-fosfokinaze, ki je bilo med prejšnjim zdravljenjem s statini višje od petkratne zgornje meje normalnih vrednosti (ZMN) (glejte poglavje 4.4).
Personal history of myopathy and/or rhabdomyolysis with statins and/or fibrates or confirmed creatine phosphokinase elevation above 5 times the upper limit of normal (ULN) under previous statin treatment (see section 4.4)
Anamneza miopatije in/ali rabdomiolize pri jemanju statinov in/ali fibratov ali potrjeno zvišanje ravni kreatin-fosfokinaze nad 5-kratnik zgornje normalne meje (ULN) pri prejšnjem zdravljenju s statini (glejte poglavje 4.4)
Personal history of myopathy and/or rhabdomyolysis with statins and/or fibrates or confirmed creatine phosphokinase elevation above 5 times the upper limit of normal (ULN) under previous statin treatment (see section 4.4)
Osebna anamneza miopatije in/ali rabdomiolize pri jemanju statinov in/ali fibratov ali potrjeno zvišanje ravni kreatin-fosfokinaze nad 5-kratnik zgornje normalne meje (ULN) pri prejšnjem zdravljenju s statini (glejte poglavje 4.4)
Personal or familial history of hereditary muscular disorders
Dedne mišične bolezni v osebni ali družinski anamnezi
Personal or familial history of hereditary muscular disorders
osebna ali družinska anamneza dednih boleznih mišic,
Personal protective equipment consisting of gloves should be worn when handling broken or damaged syringes.
Pri rokovanju z zlomljenimi ali poškodovanimi injekcijskimi brizgami nosite osebno zaščitno opremo, ki sestoji iz rokavic.
Personal protective equipment consisting of impervious gloves and a half-mask respirator conforming to European Standard EN 149 or a non- disposable respirator conforming to European Standard EN 140, with a filter conforming to European Standard EN 143 should be worn when mixing the product.
Pri mešanju zdravila nosite osebno zaščitno opremo, kot so neprepustne rokavice in dihalna polmaska skladna z evropskim standardom EN 149 ali dihalna maska skladna z evropskim standardom EN 140 s filtrom skladnim z evropskim standardom EN 143.
Personal protective equipment consisting of impervious gloves and a half-mask respirator conforming to European Standard EN 149 or a non- disposable respirator conforming to European Standard EN 140, with a filter conforming to European Standard EN 143 should be worn when mixing the product.
Pri mešanju zdravila nosite osebno zaščitno opremo, kot so neprepustne rokavice in dihalna polmaska skladno z evropskim standardom EN 149 ali dihalno masko skladno z evropskim standardom EN 140 s filtrom skladno z evropskim standardom EN 143.
Personal protective equipment consisting of impervious gloves and a half-mask respirator conforming to European Standard EN 149 or a non-disposable respirator conforming to European Standard EN 140, with a filter conforming to European Standard EN 143 should be worn when mixing the product.
Pri mešanju zdravila nosite osebno zaščitno opremo, kot so neprepustne rokavice in dihalna polmaska skladno z evropskim standardom EN 149 ali dihalno masko skladno z evropskim standardom EN 140 s filtrom skladno z evropskim standardom EN 143.
Personal protective equipment consisting of protective gloves, spectacles and boots should be worn when handling the veterinary medicinal product, before withdrawing from liquid nitrogen, during the ampoule thawing and opening operations.
Pri ravnanju z zdravilom, pred odvzemom iz tekočega dušika, pri odtajevanju ampul in med postopki odpiranja, nosite osebno zaščitno opremo, ki sestoji iz zaščitnih rokavic, zaščitnih očal in škornjev.
Personal relationships
Osebna razmerja
Personality disorder
osebnostne motnje
Personnel handling this medicinal product during dilution should wear protective clothing including mask, goggles and gloves.
Osebje, ki pripravlja in daje zdravilo, mora med redčenjem nositi zaščitna oblačila, masko, zaščitna očala in rokavice.
Personnel handling this medicinal product during dilution should wear protective clothing including mask, goggles and gloves.
Osebje, ki pripravlja in daje zdravilo, mora med rekonstitucijo nositi zaščitna oblačila, masko, zaščitna očala in rokavice.
Personnel handling this medicinal product during handling/transfer should wear protective clothing including mask, goggles and gloves.
Osebje, ki rokuje z zdravilom, mora med pripravo in aplikacijo zdravila nositi zaščitna oblačila, vključno z masko, zaščitnimi očali in rokavicami.
Personnel handling this medicinal product during reconstitution should wear protective clothing including mask, goggles and gloves.
Osebje, ki pripravlja in daje zdravilo, mora med rekonstitucijo nositi zaščitna oblačila, masko, zaščitna očala in rokavice.
Personnel handling this medicinal product during reconstitution should wear protective clothing including masks, goggles and gloves.
Osebje, ki dela s tem zdravilom, mora med rekonstitucijo nositi zaščitna oblačila, vključno z masko, očali in rokavicami.
Personnel handling this medicinal product should wear protective clothing including mask, goggles and gloves.
Osebje, ki ravna s tem zdravilom, mora nositi ustrezno zaščitno obleko, vključno z masko, očali in rokavicami.
Personnel handling this medicine during reconstitution should wear protective clothing including mask, goggles and gloves
Osebe, ki pripravljajo zdravilo, morajo nositi zaščitna oblačila, vključno z zaščitno masko, zaščitnimi očali in zaščitnimi rokavicami
Personnel involved in the treatment of vaccinated birds should follow hygiene principles and take particular care in handling litter from vaccinated chickens.
Osebe, ki sodelujejo pri rokovanju s cepljenimi pticami, naj upoštevajo osnove higiene in še posebno pazijo pri ravnanju z odpadki cepljenih piščancev.
Personnel preparing the reconstituted solution should wear surgical gloves, safety glasses and a closed front surgical-type gown with knit cuffs.
Osebje, ki pripravlja raztopino, mora nositi kirurške rokavice, varnostna očala in spredaj zaprto kirurško haljo s stisnjenimi manšetami.
personnel should be trained in good technique for handling anticancer agents;
Osebje mora biti izobraženo v tehniki dela z učinkovinami proti raku.
Personnel should be trained to dilute the medicinal product.
Osebje mora biti ustrezno izurjeno za redčenje zdravila.
Personnel should be trained to dilute the medicinal product.
Osebje mora biti ustrezno izurjeno za rekonstitucijo zdravila.
Personnel should be trained to prepare and administer the medicinal product.
Osebje mora biti usposobljeno za pripravo in dajanje zdravila.
Personnel should be trained to reconstitute the medicinal product.
Osebje mora biti usposobljeno za rekonstituiranje zdravila.
Personnel should be trained to reconstitute the medicinal product.
Osebje mora biti ustrezno izurjeno za rekonstitucijo zdravila.
Personnel should be trained to reconstitute the medicine
Osebje mora biti usposobljeno za pripravo zdravila
Persons above 60 years should start with a dose of 0.1–0.2 mg per day which should be slowly increased according to individual requirements.
Osebe, stare več kot 60 let, morajo začeti z odmerkom 0,1–0,2 mg na dan, nato pa ga počasi povečevati glede na individualne potrebe.
Persons administering the product:
Namenjena osebi, ki zdravilo daje živalim:
Persons aged 18-65 years can be vaccinated in a rapid schedule as follows: First dose at Day 0.
Odrasle med 18. in 65. letom starosti lahko cepimo po hitrem urniku, kot sledi: Prvi odmerek na dan 0.
Persons not previously vaccinated with Prepandrix
Osebe, ki predhodno niso bile cepljene s cepivom Prepandrix
Persons who have allergic reactions to injected IGF-1, who have unexpectedly high blood values of IGF-1 after injection, or who fail to show a growth response may be having an antibody response to injected IGF-1.
Pri osebah, pri katerih injiciranje IGF-1 povzroči alergijske reakcije, ki imajo po vbrizganju IGF-1 nepričakovano visoko raven IGF-1 v krvi ali se ne odzovejo z rastjo, je morda ob vbrizganju IGF-1 prišlo do odziva s protitelesi.
Persons with known hypersensitivity to quinolones should avoid any contact with the product.
Osebe z znano preobčutljivostjo za kinolone naj se izogibajo stiku z izdelkom.
Persons with known hypersensitivity to quinolones should avoid any contact with the product.
Osebe z znano preobčutljivostjo za kinolone se morajo izogibati stiku z izdelkom.
Persons with known hypersensitivity to quinolones should avoid contact with the product.
Osebe z znano preobčutljivostjo za kinolone naj se izogibajo stika z zdravilom.
Persons with known hypersensitivity to quinolones should avoid contact with the veterinary medicinal product.
Osebe z znano preobčutljivostjo za kinolone naj se izogibajo stiku z zdravilom.
Persons ≥ 653
Osebe ≥ 653
Pertussis (often called whooping cough) is a highly infectious illness that affects the airways.
Oslovski kašelj (pogosto imenovan pertusis) je zelo nalezljiva bolezen, ki prizadene dihalne poti.
Pertussis (often called whooping cough): a highly infectious illness that affects the airways.
Oslovski kašelj (imenovan tudi pertusis): zelo nalezljiva bolezen, ki prizadene dihalne poti.
pertussis (whooping cough);
oslovskemu kašlju;
pertussis (whooping cough);
oslovskim kašljem;
Pertussis response rates were similar to the control vaccine for all pertussis antigens after the booster dose.
Stopnje odziva za oslovski kašelj so bile podobne kot pri kontrolnem cepivu za vse antigene oslovskega kašlja po obnovitvenem odmerku.
Pertussis Toxoid 25 micrograms
toksoid oslovskega kašlja 25 mikrogramov
Pertuzumab exposure was reported in offspring from all treated groups, at levels of 29% to 40% of maternal serum levels at GD100.
O izpostavljenosti pertuzumabu so poročali pri mladičih vseh zdravljenih skupin, v razponu od 29- do 40 % vrednosti v serumu samic pri GD 100.
Pertuzumab has been designed to recognise and attach to HER2, a protein found on the surface of HER2-positive cancer cells.
Pertuzumab deluje tako, da prepozna HER2, tj. beljakovino na površini HER2-pozitivnih rakavih celic, in se veže nanjo.
Pertuzumab is a humanised IgG1 monoclonal antibody produced in mammalian (Chinese hamster ovary) cells by recombinant DNA technology.
Pertuzumab je humanizirano monoklonsko protitelo IgG1, pridobljeno iz celične kulture sesalcev (ovarijske celice kitajskega hrčka) s tehnologijo rekombinantne DNA.
Pertuzumab may elicit severe diarrhoea.
Pertuzumab lahko izzove hudo diarejo.
PET (polyethylene terephthalate) vial of 20 ml closed with a nitryl-based rubber stopper and sealed with an aluminium cap.
PET (polietilen tereftalat) vial z 20 ml, zaprta z nitrilnim gumijastim zamaškom in zavarjena z aluminiajsto zaporko
PET bottle containing 50 ml or 100 ml closed with a bromobutyl rubber stopper and sealed with an aluminium tear-off cap.
Plastenka PET, ki vsebuje 50 ml ali 100 ml, zaprta z zamaškom iz bromobutilne gume, zatesnjena z aluminijasto odtržno kapico.
PET bottle polypropylene measuring syringe
PET plastenka polipropilensko odmerno brizgalko
PET bottle with bromobutyl rubber stopper
PET plastenka z bromobutil nim gumijastim zamaškom
PET bottle, aluminium or white plastic screw cap
PET plastenka, z zamaškom z navojem iz aluminija ali bele plastike
PET bottles with
plastenke iz PET z
PET bottles with rubber stopper and aluminium cap
plastenke iz PET z
PET bottles with rubber stopper and aluminium cap
Plastenke iz PET z gumijastim zamaškom in aluminijasto zaporko
PET Net Muenchen GmbH - MUNICH Marchioninistrasse 15
PET Net Muenchen GmbH Marchioninistrasse 15
PET Net Muenchen GmbH, Germany
PET Net Muenchen GmbH, Nemčija
PET scans with Amyvid should only be requested by doctors skilled in the clinical management of patients with neurodegenerative diseases such as Alzheimer’s and other dementias.
Preiskave PET z zdravilom Amyvid lahko naročijo le zdravniki, ki so usposobljeni za klinično obravnavo bolnikov z nevrodegenerativnimi boleznimi, kot so Alzheimerjeva in druge demence.
PET studies in humans and preclinical data suggest that TMZ crosses rapidly the blood-brain barrier and is present in the CSF.
Študije z uporabo PET pri ljudeh in predklinični podatki nakazujejo, da TMZ hitro prehaja krvno- možgansko pregrado in je prisoten v cerebrospinalni tekočini.
PET studies in humans and preclinical data suggest that TMZ crosses rapidly, the blood-brain barrier and is present in the CSF.
Študije z uporabo PET pri ljudeh in predklinični podatki nakazujejo, da TMZ hitro prehaja krvno- možgansko pregrado in je prisoten v cerebrospinalni tekočini.
PET studies in humans and preclinical data suggest that TMZ crosses the blood-brain barrier rapidly and is present in the CSF.
Študije z uporabo PET pri človeku in predklinični podatki kažejo, da TMZ hitro prehaja hematoencefalno pregrado in da je prisoten v cerebrospinalni tekočini (CFS – »celebrospinal fluid«).
PET vial in a cardboard box
viala iz PET v zloženki
PET vials (10 ml, 50 ml) and glass vials (2 ml, 10 ml, 50 ml)
PET plastenke (10 ml, 50 ml) in steklene viale (2 ml, 10 ml, 50 ml)
PET vials of 20, 50, 100, 200 and 250 ml.
Viale iz PET po 20, 50, 100, 200 in 250 ml.
PET vials: 20 ml Polyethylene terephthalate (PET) vials, clear
PET viale: 20 ml polietilen tereftalatne (PET) prozorne viale 50 ml PET prozorne viale
PET-bottles with polypropylene child-resistant closure containing 50, 150 or 480 ml per bottle.
Plastenke iz PET, ki imajo polipropilensko za otroke varno zaporko in vsebujejo 50, 150 ali 480 ml na stekleničko.
Petechiae***
petehije
petechiae, pruritus (includes generalized), rash, ecchymosis
petehija, pruritus (vključuje generalizirani pruritus), osip, ehimoza
Petechiae; Alopecia; Drug eruption; Dermatitis^
Petehije; alopecija; izpuščaj zaradi zdravil; dermatitis^
PETG/COC.PETG/PCTFE-aluminium blister
Pretisni omot iz aluminija PETG/COC.PETG/PCTFE
pethidine or propoxyphene - used for pain
petidin ali propoksifen – uporabljata se pri bolečinah
pethidine, piroxicam, propoxyphene (used to relieve pain);
petidin, piroksikam, propoksifen (uporabljajo se za lajšanje bolečin),
Pethidine, piroxicam, propoxyphene Ritonavir co-administration is likely to result in increased plasma concentrations of pethidine, piroxicam, and propoxyphene and is therefore contraindicated (see section 4.3).
Petidin, piroksikam, propoksifen Sočasna uporaba ritonavirja ponavadi zviša koncentracijo petidina, piroksikama in propoksifena v plazmi in je zato kontraindicirana (glejte poglavje 4.3).
Pethidine, piroxicam, propoxyphene Ritonavir co-administration is likely to result in increased plasma concentrations of pethidine, piroxicam, and propoxyphene and is therefore contraindicated (see section 4.3).
Sočasna uporaba ritonavirja ponavadi zviša koncentracijo petidina, piroksikama in propoksifena v plazmi in je zato kontraindicirana (glejte poglavje 4.3).
PETNET Solutions, 91090, Lisses, France
PETNET Solutions 91090, Lisses, Francija
PETNET Solutions, 91090, Lisses, France
PETNET Solutions, 91090, Lisses, Francija
Peutz-Jeghers syndrome (a disorder that causes blockage of the bowel and where your hands, soles of your feet and surface of your lips may have brown freckles)
Peutz-Jeghersov sindrom (motnjo, ki povzroča zaporo črevesa in pri kateri so lahko na dlaneh, podplatih in površini ustnic prisotne rjave pege);
Pexion 100 mg tablets for dogs Pexion 400 mg tablets for dogs Imepitoin
Pexion 100 mg tablete za pse Pexion 400 mg tablete za pse imepitoin
Pexion has been compared to phenobarbital (another anti-epileptic medicine) in one main study, a field study involving 226 dogs of approximately 70 breeds and aged 0.8 to 15 years.
Zdravilo Pexion so primerjali s fenobarbitalom (drugim zdravilom za preprečevanje epileptičnih napadov) v eni glavni, terenski študiji, ki je vključevala 226 psov, ki so pripadali približno 70 pasmam in so bili stari od 0,8 do 15 let.
Pexion is a veterinary medicine that contains imepitoin.
Pexion je zdravilo za uporabo v veterinarski medicini, ki vsebuje imepitoin.
Pexion is used in dogs to reduce the frequency of generalised seizures (fits affecting most or all of the brain) due to epilepsy of unknown causes (idiopathic).
Zdravilo Pexion se uporablja pri psih za zmanjšanje pogostnosti generaliziranih napadov (krčev, ki prizadenejo večji del možganov ali celotne možgane) pri epilepsiji neznanega izvora (idiopatski).
Pexion must not be used in dogs that are hypersensitive (allergic) to the active ingredient or to any of the ingredients.
Zdravilo Pexion se ne sme uporabljati pri psih, ki so preobčutljivi za (alergični na) zdravilno učinkovino ali katero koli drugo sestavino zdravila.
Pexion reduced the average number of generalised seizures from 2.3 to 1.1 per month after 20 weeks of treatment compared with a reduction of 2.4 seizures to 1.1 per month with phenobarbital.
Po 20 tednih zdravljenja z zdravilom Pexion se je povprečno število generaliziranih epileptičnih napadov znižalo z 2,3 na 1,1 napada na mesec, v primerjavi s fenobarbitalom, pri katerem se je to znižalo z 2,4 na 1,1 napada na mesec.
Peyona 20 mg/ml solution for infusion and oral solution caffeine citrate
Peyona 20 mg/ml raztopina za infundiranje in peroralna raztopina kofeinijev citrat
Peyona1 caffeine citrate
Peyona1 kofein citrat
Peyronie’s disease
Peyroniejeva bolezen
Peyronie’s disease is a condition in which men develop plaques of fibrous, scar-like tissue in their penis, causing it to become abnormally curved, and sometimes leading to pain or difficulty in sexual intercourse.
Peyroniejeva bolezen je bolezen, pri kateri se pri moškem pojavijo plaki v obliki fibroznega brazgotinastega tkiva na penisu, ki se zaradi tega nenormalno ukrivi, kar včasih povzroči bolečine ali težave pri spolnem odnosu.
Peyronie’s disease occurs exclusively in adult male patients and hence there is no relevant information for use in females.
Peyroniejeva bolezen se pojavlja samo pri odraslih moških bolnikih, zato za uporabo pri ženskah ni relevantnih podatkov.
Peyronie’s disease occurs exclusively in adult male patients and hence there is no relevant use of Xiapex in the paediatric population aged 0-18 years for the treatment of Peyronie’s disease.
Peyroniejeva bolezen se pojavlja samo pri odraslih moških bolnikih, zato zdravilo Xiapex ni primerno za uporabo pri pediatrični populaciji, stari od 0-18 let, za zdravljenje Peyroniejeve bolezni.
Peyronie’s Disease Questionnaire (PDQ)b, – Mean Patient-Reported PD Bother Domain Score (range: 0-16) c
Vprašalnik za Peyroniejevo bolezen (PDQ)b, – povprečni rezultat Področja težav, kot jih poročajo bolniki (razpon: 0–16) c
Peyronie’s disease: The treatment area should be identified and marked with a surgical marker on the erected penis.
Peyroniejeva bolezen: predel zdravljenja morate določiti na nabreklem penisu in ga označiti s kirurškim markerjem.
Peyronie’s plaque
Peyroniejev plak
Pfizer bvTel: +31(0)10 406 43 01
Pfizer bvTel: +31 (0)10 406 43 01
Pfizer Global Manufacturing Weesp CJ van Houtenlaan 36
Pfizer Global Manufacturing Weesp CJ van Houtenlaan 36‌
Pfizer Limited (as MA Holder logo)
Pfizer Limited (kot logo imetnika dovoljenja za promet)
Pfizer Limited Ramsgate Road
Pfizer Ltd Ramsgate Road
Pfizer Limited, Ramsgate Rd, Sandwich, Kent, CT13 9NJ, United Kingdom
Pfizer Limited, Ramsgate Rd, Sandwich, Kent, CT13 9NJ, Velika Britanija
Pfizer Limited, Ramsgate Rd, Sandwich, Kent, CT13 9NJ, United Kingdom.
Pfizer Limited, Ramsgate Rd, Sandwich, Kent CT13 9NJ, Velika Britanija
Pfizer Limited, Ramsgate Road, Sandwich, Kent CT13 9NJ, United Kingdom
Pfizer Limited, Ramsgate Road, Sandwich, Kent CT13 9NJ, Velika Britanija
Pfizer Limited, Sandwich, Kent CT13 9NJ, United Kingdom.
Pfizer Limited, Sandwich, Kent CT13 9NJ, Velika Britanija
Pfizer Limited, Sandwich, Kent, CT13 9NJ, United Kingdom.
Pfizer Limited, Sandwich, Kent, CT13 9NJ, Velika Britanija
Pfizer Ltd (as MA Holder logo)
Pfizer Ltd (kot logo imetnika dovoljenja za promet z zdravilom)
Pfizer Ltd (as MA Holder logo)
Pfizer Ltd (kot logo imetnika dovoljenja za promet)
Pfizer Ltd (as MA Holder Logo)
Pfizer Ltd (kot logotip imetnika DzP)
Pfizer Ltd (as MA Holder logo)
Pfizer Ltd.
Pfizer Luxembourg SARL Eesti filiaal Tel.: +372 6 405 328
Pfizer Luxembourg SARL Eesti filiaal Tel: +372 6 405 328
Pfizer Luxembourg SARL filiāle Latvijā Tel.: + 371 670 35 775
Pfizer Luxembourg SARL filiāle Latvijā Tel: +371 70 35 775
Pfizer Luxembourg SARL filiāle Latvijā Tel: +371 670 35 775
Pfizer Luxembourg SARL filiāle Latvijā Tel: +371 6 70 35 775
Pfizer Luxembourg SARL, organizačná zložka
Pfizer Luxembourg SARL organizačná zložka
Pfizer Luxembourg SARL, organizačná zložka Tel.:+ 421-2-3355 5500
Pfizer Luxembourg SARL, organizačná zložka Tel: +421-2-3355 5500
Pfizer Manufacturing Deutschland GmbH, Betriebsstātte Freiburg, Mooswaldallee 1, 79090 Freiburg, Germany.
Pfizer Manufacturing Deutschland GmbH, Betriebsstātte Freiburg, Mooswaldallee 1, 79090 Freiburg, Nemčija.
Pfizer Manufacturing Deutschland GmbH, Heinrich-Mack-Strasse 35, 89257 Illertissen, Germany
Pfizer Manufacturing Deutschland GmbH, Heinrich-Mack-Strasse 35, 89257 Illertissen, Nemčija
Pfizer Pharma PFE GmbH Tel: + 49 (0) 800 8535555
Hospira Deutschland GmbH Tel: + 49 (0) 89 43 77 77 0
Pfizer S.A. / N.V. Tél/Tel: +32 2 554 62 11
Hospira Benelux BVBA Tél/Tel: + 32 3 231 90 09
Pfizer Service Company, Hoge Wei 10, B1930 Zaventem, Belgium
Pfizer Service Company, Hoge Wei 10, B1930 Zaventem, Belgija
Pfizer ΕΛΛΑΣ Α.Ε. Τηλ.: +30 210 67 85 800
Pfizer ΕΛΛΑΣ Α.Ε. Τλ: +30 210 67 85 800
Pfizer ΕΛΛΑΣ Α.Ε.Τηλ.: +30 210 67 85 800
Pfizer ΕΛΛΑΣ Α.Ε. Τλ: +30 210 67 85 800
Pflugstrasse 12,
Biokema Anstalt Pflugstrasse 12
PFS
OS
PFS (median)
PFS (mediana)
PFS - brain only Median (months)e (95% CI)d
PFS - le v možganih mediana (meseci)e (95-% IZ)d
PFS - overall Median (months)e (95% CI)d
PFS - celokupno mediana (meseci)e (95-% IZ)d
PFS according to a post-hoc, blinded, independent assessment was 8.2 months vs
PFS v skladu s post-hoc, slepo, neodvisno oceno je bil 8,2 meseca v primerjavi s 4,4 meseca; HR = 0,670; p = 0,1208.
PFS benefit was accompanied by improvement in disease-related symptoms and delayed time to deterioration (see Table 7).
Daljše preživetje brez napredovanja bolezni je spremljalo izboljšanje simptomov bolezni in podaljšalo čas do poslabšanja (glejte preglednico 7).
PFS benefit was accompanied by improvement in disease-related symptoms and delayed time to deterioration (see Table 9).
Učinkovitost PFS je bila opažena skupaj z izboljšanjem simptomov, povezanih z boleznijo, in zapoznelim časom do poslabšanja (glejte preglednico 9).
PFS data were partially confirmed by an independent review (400 / 1725 patients were randomly selected for review).
PBN podatki so bili delno potrjeni z neodvisnim pregledom (400 / 1725 bolnikov je bilo naključno izbranih za pregled).
PFS months median (95% CI)
PFS (meseci) mediana (95 % IZ)
PFS Probability
Verjetnost preživetja brez napredovanja
PFS rate at 12 months and 95% CI: 42% (36, 47)
Delež PFS v 12. mesecu in 95 % IZ: 42 % (36, 47)
PFS rate at 12 months and 95% CI: 49% (44, 55)
Delež PFS v 12. mesecu in 95 % IZ: 49 % (44; 55)
PFS rate at 6 months
Delež preživetja brez napredovanja bolezni po 6 mesecih
PFS results are shown in Figure 2 (all randomised population), Figure 3 (at the tumour PD-L1 5% cut-off), and Figure 4 (at the tumour PD-L1 1% cut-off).
Rezultati PFS so prikazani na sliki 2 (populacija vseh randomiziranih bolnikov), sliki 3 (pri mejni vrednosti PD-L1 tumorja 5 %) in sliki 4 (pri mejni vrednosti PD-L1 tumorja 1 %).
PFS was also significantly longer in patients receiving Stivarga plus BSC (hazard ratio: 0.311, p<0.000001), median PFS 3.2 months with Stivarga vs.
Preživetje brez napredovanja bolezni je bilo pomembno daljše pri bolnikih, ki so prejemali zdravilo Stivarga in najboljšo podporno oskrbo (razmerje ogroženosti: 0,311; p < 0,000001), mediana preživetja brez napredovanja bolezni